Dataset Information

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

ABSTRACT:

Background

Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments.

Patients and methods

The files of the 46 829 patients diagnosed with an FPC in the Centre Léon Bérard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted.

Results

Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 0-78 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis.

Conclusion

Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types.

SUBMITTER: Heudel P

PROVIDER: S-EPMC7844579 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

Heudel P P Chabaud S S Perol D D Flechon A A Fayette J J Combemale P P Tredan O O Desseigne F F de la Fouchardiere C C Boyle H H Perol M M Bachelot T T Cassier P P Avrillon V V Terret C C Michallet A-S AS Neidhardt-Berard E-M EM Nicolas-Virelizier E E Dufresne A A Belhabri A A Brahmi M M Lebras L L Nicolini F F Sarabi M M Rey P P Bonneville-Levard A A Rochefort P P Provensal A-M AM Eberst L L Assaad S S Swalduz A A Saintigny P P Toussaint P P Guillermin Y Y Castets M M Coutzac C C Meeus P P Dupré A A Durand T T Crochet H H Fervers B B Gomez F F Rivoire M M Gregoire V V Claude L L Chassagne-Clement C C Pilleul F F Mognetti T T Russias B B Soubirou J-L JL Lasset C C Chvetzoff G G Mehlen P P Beaupère S S Zrounba P P Ray-Coquard I I Blay J-Y JY

ESMO open 20210127 1

<h4>Background</h4>Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments.<h4>Patients and methods</h4>The files of the 46 829 patients diagnosed with an FPC in the Centre Léon Bérard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened usin ...[more]

PMID: 33516148

Similar Datasets

Project description:Despite lengthening survival, death rates from metastatic colorectal cancer (CRC) remain unacceptably high, with a bright spot being the demonstration of durable responses in patients with CRC who have mismatch repair-deficient (dMMR) and/or microsatellite instability-high (MSI-H) tumors and are treated with immune checkpoint inhibitor therapy. Nivolumab and pembrolizumab, as well as nivolumab in combination with low-dose ipilimumab-all checkpoint inhibitors-are currently approved by the U.S. Food and Drug Administration (FDA) for patients with MSI-H/dMMR metastatic CRC that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Nonetheless, there are a number of questions and considerations in the use of these checkpoint inhibitor therapies. Using a question-and-answer format, this review summarizes the scientific rationale for immune checkpoint inhibitor therapy in CRC, including the effects of tumor factors such as genetic aberrations and mutational load on the immune response, particularly in patients with MSI-H/dMMR disease. We discuss response patterns, response criteria, and immune-related adverse events using findings from published efficacy and safety data of immune checkpoint inhibitor therapy in metastatic CRC. We also discuss issues surrounding treatment sequencing, incorporating approved checkpoint inhibitors into the current treatment paradigm, and the multiple investigational strategies that may optimize immunotherapy for advanced CRC in the future, including novel combination therapies. IMPLICATIONS FOR PRACTICE: Colorectal cancer (CRC) is the third most common cancer in the U.S. Despite advances in chemotherapy, survival remains poor for patients with metastatic CRC. Certain immunotherapy agents have demonstrated long-lasting responses in previously treated patients with immune-responsive microsatellite instability-high/mismatch repair-deficient metastatic CRC, leading to U.S. Food and Drug Administration approval of the immune checkpoint inhibitors nivolumab (with or without low-dose ipilimumab) and pembrolizumab in this population. Combination therapy (e.g., nivolumab with low-dose ipilimumab) has demonstrated numerically higher response rates and improved long-term clinical benefit relative to anti-programmed death-1 monotherapy. Ongoing trials are evaluating immunotherapy in the broader CRC population and novel combinations to optimize immunotherapy for advanced CRC.

Dataset Information

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

Background

Patients and methods

Results

Conclusion

Publications

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets